FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1693-1699

  Stintzing, S ^a   Fischer von weikersthal, L ^b   Decker, T ^c   Vehling kaiser, U ^d   Jager E ^e   Heintges, T ^f   Stoll, C ^g   Giessen, C ^a   Modest, D P ^a   Neumann, J ^h   Jung, A ^h   Kirchner, T ^h   Scheithauer, W ⁱ   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Gesundheitszentrum St Marien   (Germany)

^c Onkologie Ravensburg   (Germany)

^d Onkologische Praxis   (Germany)

^e KRANKENHAUS NORDWEST   (Germany)

^f Städtisches Klinikum Neuss   (Germany)

^g Zentrum für medizinische Rehabilitation   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bevacizumab; Cetuximab; Colon cancer; First line; FOLFIRI; MCRC

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ACNE; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; CODON; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84861318872     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr571     Document Type: Article

References (18)

1. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
2. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
3. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
4. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16: 3133-3143.
5. Moosmann N, Fischer von Weikersthal L, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - a randomized trial of the German AIO CRC Study Group. J Clin Oncol 2011; 29 (8): 1050-1058.
6. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-fluorouracil/ folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII Study (NCT00145314). Ann Oncol 2010; 21Suppl 8(Abstr LBA20). 35th ESMO Conference 2010, Edition. Milan, Italy
7. Maughan T, Adams R, Smith C et al. The addition of cetuximab to oxaliplatinfluoropyrimidine chemotherapy in first-line advanced colorectal cancer in the MRC COIN trial: identification of potentially responsive subsets of patients. Ann Oncol 2010; 21: 17-18.
8. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
9. Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in firstline metastatic colorectal cancer. Oncology 2009; 77: 113-119.
10. Lopez R, Salgado M, Reboredo M et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010; 103: 1536-1541.
11. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-28.
12. Reinacher-Schick A, Schmiegel W Impact of KRAS status on survival in patients ( pts.) with metastatic colorectal cancer (mCRC) undergoing bevacizumab (bev) containing chemotherapy regimen-analysis of the AIO Colorectal Cancer Study Group. Ann Oncol 2010; 21 (Suppl 8) (Abstr 585PD)
13. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
14. Jung A, Baretton G, Dietel M et al. The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cancer. J Clin Oncol 2009; 27Suppl15s. (Abstr 4018). 2009 ASCO Annual Meeting
15. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
16. Stathopoulos GP, Batziou C, Trafalis D et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376-381.
17. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820.
18. Tejpar S, Bokemeyer C, Celik I et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with firstline chemotherapy with or without cetuximab. J Clin Oncol 2011; 29 (Suppl) (Abstr 3511)